Molina Healthcare (MOH) recently reported first quarter 2026 results that beat earnings expectations, supported by disciplined medical cost management, and reaffirmed its full year adjusted EPS guidance despite lower revenue forecasts and Medicaid membership attrition.

The strong first quarter earnings beat and reiterated adjusted EPS guidance have been met with a sharp shift in sentiment, with a 31.3% 1 month share price return. This contrasts with a 1 year total shareholder return decline of 44.1%, suggesting recent momentum is building from a much weaker long term performance base.

If Molina’s rebound has you reassessing healthcare, it can be useful to see what else is moving and how, starting with 33 healthcare AI stocks

With Molina trading at $175.94 against an analyst price target of $161.60, yet with an indicated 57% intrinsic discount and a weak multiyear return profile, is this a reset entry point, or is the market already baking in future growth?

Most Popular Narrative: 57.3% Undervalued

According to the narrative, Molina’s fair value of $411.65 sits far above the last close at $175.94, with the gap linked to a long term growth view built on government backed programs and membership scale.

Molina Healthcare’s annual revenue has been on an upward trajectory. In 2023, their revenue reached $34.072 billion, reflecting a 6.56% increase from 2022.

Considering this trend, we can make an informed estimate for the next five years. However, please note that predicting exact figures is challenging due to various factors (market dynamics, regulatory changes, etc.).

Want to see why this narrative places such a large gap between price and value? It focuses on compounding revenue, expanding programs, and firmer profitability assumptions that are very specific to Molina’s government contract model.

Result: Fair Value of $411.65 (UNDERVALUED)

However, this depends on a favorable regulatory environment and stable medical costs, and changes in either could quickly undermine those optimistic revenue and earnings assumptions.

Another View: Earnings Multiple Sends a Different Signal

While the SWS DCF model sees Molina as 57% undervalued, the P/E picture is far less forgiving. At 48.7x, the P/E is roughly double peer and industry levels of 23.2x and 24.3x, and it also sits well above the 31x fair ratio the market could move toward.

If price eventually leans closer to that fair ratio, does the DCF upside still feel as comfortable, or does it point to higher valuation risk than the headline discount suggests?

Next Steps

With mixed signals on valuation and sentiment running hot again, now is the time to look under the hood yourself and pressure test the story. To see how the upside case stacks up against the concerns the market is flagging, start with the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If Molina has sharpened your focus, do not stop here. A few targeted screens can quickly surface fresh companies that might suit your next move.

• Target higher potential income by checking out companies offering steady payouts and strong yields through the 13 dividend fortresses.
• Zero in on quality at a discount by scanning companies that look attractively priced using the 54 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses with stronger finances via the solid balance sheet and fundamentals stocks screener (42 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.